A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Latest Information Update: 23 Dec 2024
Price :
$35 *
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors BeiGene
- 23 Dec 2024 New trial record